+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are establishing a bidirectional cohort study focused on Gestational Trophoblastic Neoplasia GTN, including both past cases and new patient groups. This study aims to create a unified clinical collaboration system across multiple tertiary hospitals to standardize diagnosis, treatment, and follow-up for GTN patients. The goal is to build a comprehensive clinical database, identify factors linked to chemotherapy resistance, and develop precise evaluation models to improve initial treatment outcomes. The study collects detailed baseline information from GTN patients, such as age, reproductive history, environmental and social factors, genetic data, physical exams, imaging, and pathology results. Biological samples like blood and tissue will also be gathered. During diagnosis and treatment, data on treatment plans, human chorionic gonadotropin hCG levels, and any toxic side effects will be recorded. After treatment, patients will be followed closely with monthly hCG level checks in the first year and then every three months for up to five years, alongside imaging and fertility assessments. Participants will provide ongoing information about their disease status, treatment responses, and long-term outcomes, including recurrence and metastasis. This data will be used to track prognosis and develop a standardized follow-up system for GTN. The primary outcome measure focuses on collecting detailed clinical and pathological features with a structured follow-up schedule to support evidence-based improvements in GTN care. The study is observational and led by the Womens Hospital School of Medicine Zhejiang University.

Age: 18Years +FEMALE
1 location
S

Actively Recruiting

Researchers are studying the use of Tenecteplase TNK combined with Butylphthalide NBP in patients who have experienced mild disabling acute ischemic stroke AIS. This large, randomized, double-blind trial compares the effects of TNK plus NBP versus TNK alone to see if the combination improves neurological function and recovery. Patients eligible for the study are adults aged 18 to 80 years who have had a stroke within 4.5 hours and meet specific neurological severity criteria. Participants are randomly assigned to one of two groups. The combination group receives a single intravenous dose of TNK followed by intravenous NBP twice daily for 7 days, then oral NBP capsules three times daily until Day 14. The control group receives the same TNK dose followed by a matching placebo infusion and capsules on the same schedule. Treatments are administered during hospitalization and continue after discharge if needed. Throughout the 90-day study period, participants undergo assessments including stroke severity scores, functional recovery measured by the Modified Rankin Scale, quality of life surveys, and imaging to evaluate brain tissue salvage. Safety monitoring tracks adverse events like bleeding or vascular complications. The main outcome is the proportion of patients achieving minimal disability by 90 days, with additional evaluations of neurological improvement and stroke recurrence.

Age: 18Years - 80YearsAll GendersPhase 3
15 locations